Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp

Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovag...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Leah M., Orenstein, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445446/
https://www.ncbi.nlm.nih.gov/pubmed/36059275
http://dx.doi.org/10.1177/23247096221123144
_version_ 1784783424659128320
author Grant, Leah M.
Orenstein, Robert
author_facet Grant, Leah M.
Orenstein, Robert
author_sort Grant, Leah M.
collection PubMed
description Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.
format Online
Article
Text
id pubmed-9445446
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-94454462022-09-07 Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp Grant, Leah M. Orenstein, Robert J Investig Med High Impact Case Rep Case Report Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp. SAGE Publications 2022-09-03 /pmc/articles/PMC9445446/ /pubmed/36059275 http://dx.doi.org/10.1177/23247096221123144 Text en © 2022 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Grant, Leah M.
Orenstein, Robert
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
title Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
title_full Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
title_fullStr Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
title_full_unstemmed Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
title_short Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
title_sort treatment of recurrent vulvovaginal candidiasis with ibrexafungerp
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445446/
https://www.ncbi.nlm.nih.gov/pubmed/36059275
http://dx.doi.org/10.1177/23247096221123144
work_keys_str_mv AT grantleahm treatmentofrecurrentvulvovaginalcandidiasiswithibrexafungerp
AT orensteinrobert treatmentofrecurrentvulvovaginalcandidiasiswithibrexafungerp

Ejemplares similares